SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Nov 17, 2017
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: Nov. 17, 2017 · CIK: 0001213037 · Accession: 0001193125-17-347080
AI Filing Summary & Sentiment
File numbers found in text: 333-221115
Letter
Securities and Exchange Commission Attention: Christine Westbrook Re: Trovagene, Inc. Registration Statement on Form S-1 Filed October 25, 2017 File No. 333-221115
Dear Ms. Westbrook:
This letter sets forth the responses of Trovagene, Inc., a Delaware corporation (the “Company” or “we”), to the comments received from the Staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) on November 7, 2017 concerning the Company’s registration statement on Form S-1.
Form S-1 filed 10/25/2017
Cover Page
1. It appears that shares of common stock and warrants will be offered and priced together as a unit. Please amend your registration statement to add units or tell us why such disclosure is not required. Please also revise your cover page disclosure to include the method by which the price of the securities is to be determined. Refer to Instruction 2 to Item 501(b)(3) of Regulation S-K.
Amendment No. 1 to Form S-1 has been modified to add units. In addition, we have added disclosure to the front cover page of the prospectus describing the method by which the price of the securities will be determined.
2. We note your disclosure on page 38 that H.C. Wainwright & Co., LLC will use its reasonable best efforts to arrange for the sale of the securities offered by the prospectus. Please also revise the cover page to include all of the information required by Item 501(b)(8) of Regulation S-K.
We have revised the front cover page of the prospectus in Amendment No. 1 to Form S-1 to include the information required by Item 501(b)(8) of Regulation S-K.
Sincerely,
/s/ Jeffrey J. Fessler
Show Raw Text
CORRESP 1 filename1.htm CORRESP Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, NY 10112 November 17, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Christine Westbrook Re: Trovagene, Inc. Registration Statement on Form S-1 Filed October 25, 2017 File No. 333-221115 Dear Ms. Westbrook: This letter sets forth the responses of Trovagene, Inc., a Delaware corporation (the “Company” or “we”), to the comments received from the Staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) on November 7, 2017 concerning the Company’s registration statement on Form S-1. Form S-1 filed 10/25/2017 Cover Page 1. It appears that shares of common stock and warrants will be offered and priced together as a unit. Please amend your registration statement to add units or tell us why such disclosure is not required. Please also revise your cover page disclosure to include the method by which the price of the securities is to be determined. Refer to Instruction 2 to Item 501(b)(3) of Regulation S-K. Amendment No. 1 to Form S-1 has been modified to add units. In addition, we have added disclosure to the front cover page of the prospectus describing the method by which the price of the securities will be determined. 2. We note your disclosure on page 38 that H.C. Wainwright & Co., LLC will use its reasonable best efforts to arrange for the sale of the securities offered by the prospectus. Please also revise the cover page to include all of the information required by Item 501(b)(8) of Regulation S-K. We have revised the front cover page of the prospectus in Amendment No. 1 to Form S-1 to include the information required by Item 501(b)(8) of Regulation S-K. Sincerely, /s/ Jeffrey J. Fessler Jeffrey J. Fessler